口服蛋白质·胜肽的全球市场:各有效成分，製剂类别，各输送技术，治疗各适应症，各地区，机会，预测，2018年～2032年

全球口服蛋白质·胜肽市场，是预测期间2025-2032年的年复合成长率成为13.66％，从2024年的66亿7,000万美元2032年185亿8,000万美元成长。口服蛋白质和胜肽，是代替注射以锭剂和胶囊的形式从口摄取的治疗用生物分子。

口服胜肽和蛋白质，与更优秀医疗服务递送技术，容易利用的治疗解决方案的患者的关注高涨互相结合，完成着在全世界大幅度的市场成长。口服蛋白质·胜肽治疗，为了比注射药简便都，成为对管理慢性疾病的患者来说有利的选项。与癌症和肠胃障碍并列在糖尿病的治疗中，口服胜肽製剂，为了带来更佳治疗成绩和药物吸收的改善，也带来着大的利益。

在创新的封装技术和根据渗透催化剂的开发，解决长的间继续了的营养吸收的困难村落酵素分解的问题的事上成功了。主要製药企业一方面对研究开发投入大金额的资金扩大产品线，确立跟生物科技企业的策略性联盟使之加速着市场进入。

北美和欧洲的医疗系统，到那个强力的基础设施和医疗研究根据进行大金额的投资的能力，领导着市场。亚太地区的医疗领域，根据医疗意识的高涨和该地区的投资活动的活跃，表示着有前途的成长预测。

顺着慢性疾病增加的一个方法前进着，医疗产业一般认为因为个人化医疗提供系统转移，儘管是法规的复杂荚製造上的课题，市场成长继续。譬如，2023年Eli Lilly and CompanyDice 以24亿美元收买Therapeutics，对治疗口服胜肽治疗，尤其是自体免疫疾病的IL-17抑制剂表现着深的关心。产业，表示着比感到患者注射药方便的新的治疗选择的动机都。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 美国的关税的影响

第4章 摘要整理

第5章 全球口服蛋白质·胜肽的展望，2018年～2032年

• 市场规模分析与预测
  • 各金额
• 市场占有率分析与预测
  • 各有效成分
    • Semaglutide
    • Linaclotide
    • 抑钙素
    • Octreotide
    • 其他
  • 製剂类别
    • 锭剂
    • 胶囊
    • 口服悬浮液/溶液
  • 各输送技术
    • 肠溶涂布系统
    • 奈米粒子/电信业者为基础的输送(给药)
    • 粘膜附着技术
    • 其他
  • 治疗各适应症
    • 糖尿病
    • 肠胃障碍
    • 骨骼代谢疾病
    • 内分泌疾病
    • 遗传性疾病·罕见疾病
    • 其他
  • 各地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲
  • 各企业的市场占有率分析(前五名公司·其他 - 各金额，2024年)
• 2024年的市场地图分析
  • 各有效成分
  • 製剂类别
  • 各输送技术
  • 治疗各适应症
  • 各地区

第6章 北美的口服蛋白质·胜肽的展望，2018年～2032年

• 市场规模分析与预测
  • 各金额
• 市场占有率分析与预测
  • 各有效成分
    • Semaglutide
    • Linaclotide
    • 抑钙素
    • Octreotide
    • 其他
  • 製剂类别
    • 锭剂
    • 胶囊
    • 口服悬浮液/溶液
  • 各输送技术
    • 肠溶涂布系统
    • 奈米粒子/电信业者为基础的输送(给药)
    • 粘膜附着技术
    • 其他
  • 治疗各适应症
    • 糖尿病
    • 肠胃障碍
    • 骨骼代谢疾病
    • 内分泌疾病
    • 遗传性疾病·罕见疾病
    • 其他
  • 各国占有率
    • 美国
    • 加拿大
    • 墨西哥
• 各国市场评估
  • 美国的口服蛋白质·胜肽的展望，2018年～2032年
    • 市场规模分析与预测
    • 市场占有率分析与预测
  • 加拿大
  • 墨西哥

第7章 欧洲的口服蛋白质·胜肽的展望，2018年～2032年

• 德国
• 法国
• 义大利
• 英国
• 俄罗斯
• 荷兰
• 西班牙
• 土耳其
• 波兰

第8章 亚太地区的口服蛋白质·胜肽的展望，2018年～2032年

• 印度
• 中国
• 日本
• 澳洲
• 越南
• 韩国
• 印尼
• 菲律宾

第9章 南美的口服蛋白质·胜肽的展望，2018年～2032年

• 巴西
• 阿根廷

第10章 中东·非洲的口服蛋白质·胜肽的展望，2018年～2032年

• 沙乌地阿拉伯
• 阿拉伯联合大公国
• 南非

第11章 需求供给分析

第12章 供应链分析

第13章 价值链分析

第14章 波特的五力分析

第15章 大环境分析

第16章 价格分析

第17章 市场动态

• 推动市场要素
• 市场课题

第18章 市场趋势与发展

第19章 法律规范

• 法规核准Scenario
• 法规当局的认证

第20章 专利的形势

第21章 案例研究

第22章 竞争情形

• 前五名市场领导公司的竞争矩阵
• 前五名公司的SWOT分析
• 前十大主要企业的形势
  • Novo Nordisk A/S
  • Pfizer Inc.
  • AbbVie Inc.
  • Merck &Co., Inc.
  • Johnson &Johnson Services, Inc.
  • Biocon Limited
  • Synergy Pharmaceuticals Inc.
  • Oramed Pharmaceuticals Inc.
  • Acadia Pharmaceuticals Inc.
  • Proxima Concepts Limited

第23章 策略性建议

第24章 关于调查公司·免责声明

Global oral proteins and peptides market is projected to witness a CAGR of 13.66% during the forecast period 2025-2032, growing from USD 6.67 billion in 2024 to USD 18.58 billion in 2032. Oral proteins and peptides are therapeutic biomolecules taken through the mouth in the form of tablets and capsules instead of injections.

Oral peptides and proteins are experiencing substantial market growth worldwide because of better medical delivery techniques combined with growing patient interest in accessible therapeutic solutions. Oral protein and peptide treatment has become the preferred option for patients who manage chronic conditions because of its simplicity over injectable medications. The treatment of diabetes alongside cancer and gastrointestinal disorders benefits greatly from oral peptide formulations because they provide better therapeutic outcomes and improved drug absorption.

The development of innovative encapsulation technologies and penetration enhancers has successfully resolved nutritional absorption difficulties and enzymatic degradation problems that lasted for a long time. Leading pharmaceutical companies dedicate substantial funding to research and development to grow their product lines while establishing strategic alliances with biotechnology organizations to speed up market entry.

The healthcare systems of North America and Europe lead the market because of their strong infrastructure and their ability to invest heavily in medical research. The healthcare domain of the Asia-Pacific region shows promising growth prospects because of increased healthcare awareness combined with growing investment activities in the region.

Market growth will continue despite regulatory complexity and manufacturing challenges since chronic diseases keep increasing, and the healthcare industry is moving toward personalized medicine delivery systems. For instance, in 2023, Eli Lilly and Company purchased Dice Therapeutics for USD 2.4 billion to demonstrate their deep interest in oral peptide therapy, especially for IL-17 inhibitors, which treat autoimmune conditions. The industry demonstrates a movement toward new treatment options, which patients find more convenient than injectable drugs.

Rising Prevalence of Chronic Disease Boosts Market Demand

The rising prevalence of chronic disease is increasing due to diabetes, cardiovascular disorders, obesity, and gastrointestinal conditions, which will boost the need for oral proteins and peptides as a more user-friendly treatment alternative to injections. The healthcare system faces a growing disease burden because of modern sedentary living habits, which are paired with unhealthy eating patterns and rising stress levels while dealing with an aging population. For instance, according to the International Diabetes Federation, about 539 million adults are currently dealing with diabetes, and the number is expected to increase to 853 million by the year 2050. The growing diabetes epidemic supports the increased market sales of oral peptide therapeutics such as GLP-1 agonists.

Furthermore, cancer and autoimmune diseases are also less common, and advanced biologic treatments are needed as the second line of treatment. With compliance factors encountered with injectable biologics, traditional injectable alternatives are an attractive option for continuous, long-term treatment. Health providers and governments are putting patients first, which is driving R&D to deliver oral protein more quickly. These trends quickly require innovative, non-invasive therapies to prevent chronic disease and boost market demand effectively.

Advancement in Drug Discovery Technology to Uplift Market Expansion

Expected growth in the oral proteins and peptides market will be fueled by modern advancements in drug discovery techniques. New technologies such as AI-enabled drug design, high-throughput screening, and computational modeling support the identification of peptides closer to any notion of stability and bioavailability. New delivery systems such as nanoparticle carriers and permeation enhancers allow peptides to overcome traditional challenges, including poor absorption and enzymatic degradation after oral administration. Formulation technologies such as enteric coatings and protease inhibitors improve oral bioavailability as well. In addition, biotech companies are also tapping into unique CRISPR and mRNA platforms to develop next-generation peptide therapeutics.

Additionally, key players are focusing on advanced technology for the development of oral proteins and peptides. For instance, in June 2024, Biora Therapeutics, Inc. announced the results of preclinical trials of its latest technology, the BioJet Systemic Oral Delivery Platform, at the Next Gen Peptide Formulation & Delivery conference. This technology is used as an ingestible device designed to transit through the digestive system and activate in the small intestine. Such advanced technology increased the potential of oral protein and peptides therapies in targeted delivery, by providing alternatives to injections and expanding the uses of various medical treatments.

Tablets Hold the Largest Market Share of the Oral Protein and Peptides Market

The oral protein and peptides market is dominated by tablets due to limitations of the oral form of protein and peptides, so they are most common. Tablets' unique solid dosage form allows a lot more convenience in administration, provides longer shelf stability than liquids or powders, with precise dosage, and if needed, doesn't need to be refrigerated. Innovations (technologies) in formulating biomolecules (enteric and controlled release formulation technologies) have impacted biologically sensitive biomolecules and their capability to produce sensitive biomolecules and novel forms of sensitive biologic oral delivery. Tablets are also less expensive to manufacture and ship than a vial or liquid drug, which makes them the most developed and accepted delivery form for pharmaceutical companies, because there are accepted manufacturing, distribution, and marketing pathways for tablets. While there are some alternative formats also available today (i.e., capsules, oral films), tablets or solid dosage forms are the historically most trusted and accepted dosage form for chronic treatments (demand for protein and peptide delivery by the oral route).

For instance, in April 2025, Merck & Co., Inc. announced that peptide drugs may soon be available in convenient oral tablet form through a USD 493 million licensing deal with Austria-based drug delivery technology maker Cyprumed.

North America Dominates the Oral Proteins and Peptides Market

North America is dominant in the global oral proteins and peptides market due to its cutting-edge healthcare infrastructure, strong research and development capabilities, and high demand for advanced biological therapies. The established pharmaceutical sector, along with flexible regulations in this region, allows quick development and market entry of novel oral protein-based medical solutions. The increasing occurrence of chronic diseases, especially diabetes and gastrointestinal disorders, creates a growing market for convenient oral peptide treatment options. North America strengthens its market leadership through major biotechnology investments and the rising popularity of non-invasive drug delivery methods. The region remains dominant in the emerging oral proteins and peptides industry through continuous drug formulation technology combined with expanding clinical applications.

Additionally, most of the pharmaceutical companies' headquarters are in North America. Along with the key industry players, numerous medical research organizations are propelling market growth by launching new products or innovative research. For instance, in February 2024, Johnson & Johnson Services, Inc., presented phase 2b FRONTIER 1 trial results for JNJ-2113, the first oral peptides under development for the treatment of moderate to severe plaque psoriasis (PsO).

Impact of U.S. Tariffs on Oral Proteins and Peptides Market

The global protein and peptide market shows significant disruptions due to the U.S. tariff implementation because it affects supply networks and generates cost spikes for manufacturers and end consumers. Organizations today need to select between absorbing their higher expenses and shifting these costs to their customers because current elevated tariffs apply to finished goods and raw materials, resulting in lower market effectiveness. The economic effects of U.S. import changes have generated difficulties for developing countries that rely heavily on American products, so these nations have begun to change their trading approaches and discover fresh supply chain options. The implementation of new tariffs has both encouraged local production development and produced financial challenges for small enterprises to handle their debts. The new policy introduces market instability that lowers growth trajectories while it demands that business stakeholders make strategic adjustments for the altered trade conditions.

Key Players Landscape and Outlook

The leading participants within the oral protein and peptides sector apply various tactics to enhance their market standing and maintain their long-term sustainability. Companies are investing in research and development alongside strategic partnerships and market expansion efforts to fuel their innovative activities in this sector. Companies protect their competitive position by obtaining exclusive rights through patent registration that enables them to maintain market control. The companies choose to work with local manufacturers in emerging markets to achieve two important objectives, which include lowering costs and expanding treatment availability to more patients.

For instance, in February 2025, Oramed Pharmaceuticals Inc. announced a joint venture with Hefei Tianhui Biotech Co. Ltd. to spin off its Protein Oral Delivery technology, which aims to redefine diabetes care and transform the future of oral biologics and chronic disease management.

For instance, in December 2024, Merck & Co., Inc. and Hansoh Pharma jointly announced that they are entering into a global licensing agreement for HS-10535, an investigational oral GLP-1 receptor agonist.

For instance, in May 2025, Novo Nordisk A/S is preparing to launch its Wegovy, a blockbuster weight loss medication, in the upcoming years 2026 for the treatment of obesity.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Oral Proteins and Peptides Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Active Ingredient
    • 5.2.1.1. Semaglutide
    • 5.2.1.2. Linaclotide
    • 5.2.1.3. Calcitonin
    • 5.2.1.4. Octreotide
    • 5.2.1.5. Others
  • 5.2.2. Formulation Type
    • 5.2.2.1. Tablets
    • 5.2.2.2. Capsules
    • 5.2.2.3. Oral Suspensions/Solutions
  • 5.2.3. By Delivery Technology
    • 5.2.3.1. Enteric Coating Systems
    • 5.2.3.2. Nanoparticle/Carrier-Based Delivery
    • 5.2.3.3. Mucoadhesive Technologies
    • 5.2.3.4. Others
  • 5.2.4. By Therapeutic Indication
    • 5.2.4.1. Diabetes Mellitus
    • 5.2.4.2. Gastrointestinal Disorders
    • 5.2.4.3. Bone Metabolic Diseases
    • 5.2.4.4. Endocrine Disorders
    • 5.2.4.5. Genetic and Rare Diseases
    • 5.2.4.6. Others
  • 5.2.5. By Region
    • 5.2.5.1. North America
    • 5.2.5.2. Europe
    • 5.2.5.3. Asia-Pacific
    • 5.2.5.4. South America
    • 5.2.5.5. Middle East and Africa
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Active Ingredient
  • 5.3.2. By Formulation Type
  • 5.3.3. By Delivery Technology
  • 5.3.4. By Therapeutic Indication
  • 5.3.5. By Region

6. North America Oral Proteins and Peptides Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Active Ingredient
    • 6.2.1.1. Semaglutide
    • 6.2.1.2. Linaclotide
    • 6.2.1.3. Calcitonin
    • 6.2.1.4. Octreotide
    • 6.2.1.5. Others
  • 6.2.2. Formulation Type
    • 6.2.2.1. Tablets
    • 6.2.2.2. Capsules
    • 6.2.2.3. Oral Suspensions/Solutions
  • 6.2.3. By Delivery Technology
    • 6.2.3.1. Enteric Coating Systems
    • 6.2.3.2. Nanoparticle/Carrier-Based Delivery
    • 6.2.3.3. Mucoadhesive Technologies
    • 6.2.3.4. Others
  • 6.2.4. By Therapeutic Indication
    • 6.2.4.1. Diabetes Mellitus
    • 6.2.4.2. Gastrointestinal Disorders
    • 6.2.4.3. Bone Metabolic Diseases
    • 6.2.4.4. Endocrine Disorders
    • 6.2.4.5. Genetic and Rare Diseases
    • 6.2.4.6. Others
  • 6.2.5. By Country Share
    • 6.2.5.1. United States
    • 6.2.5.2. Canada
    • 6.2.5.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Oral Proteins and Peptides Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Active Ingredient
        • 6.3.1.2.1.1. Semaglutide
        • 6.3.1.2.1.2. Linaclotide
        • 6.3.1.2.1.3. Calcitonin
        • 6.3.1.2.1.4. Octreotide
        • 6.3.1.2.1.5. Others
      • 6.3.1.2.2. By Formulation Type
        • 6.3.1.2.2.1. Tablets
        • 6.3.1.2.2.2. Capsules
        • 6.3.1.2.2.3. Oral Suspensions/Solutions
      • 6.3.1.2.3. By Delivery Technology
        • 6.3.1.2.3.1. Enteric Coating Systems
        • 6.3.1.2.3.2. Nanoparticle/Carrier-Based Delivery
        • 6.3.1.2.3.3. Mucoadhesive Technologies
        • 6.3.1.2.3.4. Others
      • 6.3.1.2.4. By Therapeutic Indication
        • 6.3.1.2.4.1. Diabetes Mellitus
        • 6.3.1.2.4.2. Gastrointestinal Disorders
        • 6.3.1.2.4.3. Bone Metabolic Diseases
        • 6.3.1.2.4.4. Endocrine Disorders
        • 6.3.1.2.4.5. Genetic and Rare Diseases
        • 6.3.1.2.4.6. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Oral Proteins and Peptides Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Oral Proteins and Peptides Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Oral Proteins and Peptides Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Oral Proteins and Peptides Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Supply Chain Analysis

13. Value Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

• 17.1. Market Drivers
• 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework

• 19.1. Regulatory Approval Scenario
• 19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

• 22.1. Competition Matrix of Top 5 Market Leaders
• 22.2. SWOT Analysis for Top 5 Players
• 22.3. Key Players Landscape for Top 10 Market Players
  • 22.3.1. Novo Nordisk A/S
    • 22.3.1.1. Company Details
    • 22.3.1.2. Key Management Personnel
    • 22.3.1.3. Products and Services
    • 22.3.1.4. Financials (As Reported)
    • 22.3.1.5. Key Market Focus and Geographical Presence
    • 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 22.3.2. Pfizer Inc.
  • 22.3.3. AbbVie Inc.
  • 22.3.4. Merck & Co., Inc.
  • 22.3.5. Johnson & Johnson Services, Inc.
  • 22.3.6. Biocon Limited
  • 22.3.7. Synergy Pharmaceuticals Inc.
  • 22.3.8. Oramed Pharmaceuticals Inc.
  • 22.3.9. Acadia Pharmaceuticals Inc.
  • 22.3.10. Proxima Concepts Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

23. Strategic Recommendations

24. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 3. Global Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 4. Global Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 5. Global Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 6. Global Oral Proteins and Peptides Market Share (%), By Region, 2018-2032F
• Figure 7. North America Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 8. North America Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 9. North America Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 10. North America Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 11. North America Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 12. North America Oral Proteins and Peptides Market Share (%), By Country, 2018-2032F
• Figure 13. United States Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 14. United States Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 15. United States Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 16. United States Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 17. United States Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 18. Canada Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 19. Canada Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 20. Canada Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 21. Canada Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 22. Canada Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 23. Mexico Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Mexico Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 25. Mexico Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 26. Mexico Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 27. Mexico Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 28. Europe Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Europe Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 30. Europe Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 31. Europe Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 32. Europe Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 33. Europe Oral Proteins and Peptides Market Share (%), By Country, 2018-2032F
• Figure 34. Germany Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 35. Germany Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 36. Germany Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 37. Germany Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 38. Germany Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 39. France Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 40. France Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 41. France Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 42. France Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 43. France Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 44. Italy Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Italy Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 46. Italy Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 47. Italy Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 48. Italy Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 49. United Kingdom Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 50. United Kingdom Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 51. United Kingdom Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 52. United Kingdom Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 53. United Kingdom Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 54. Russia Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 55. Russia Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 56. Russia Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 57. Russia Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 58. Russia Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 59. Netherlands Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 60. Netherlands Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 61. Netherlands Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 62. Netherlands Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 63. Netherlands Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 64. Spain Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 65. Spain Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 66. Spain Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 67. Spain Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 68. Spain Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 69. Turkey Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Turkey Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 71. Turkey Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 72. Turkey Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 73. Turkey Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 74. Poland Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 75. Poland Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 76. Poland Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 77. Poland Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 78. Poland Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 79. South America Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 80. South America Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 81. South America Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 82. South America Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 83. South America Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 84. South America Oral Proteins and Peptides Market Share (%), By Country, 2018-2032F
• Figure 85. Brazil Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 86. Brazil Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 87. Brazil Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 88. Brazil Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 89. Brazil Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 90. Argentina Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 91. Argentina Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 92. Argentina Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 93. Argentina Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 94. Argentina Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 95. Asia-Pacific Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 96. Asia-Pacific Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 97. Asia-Pacific Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 98. Asia-Pacific Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 99. Asia-Pacific Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 100. Asia-Pacific Oral Proteins and Peptides Market Share (%), By Country, 2018-2032F
• Figure 101. India Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 102. India Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 103. India Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 104. India Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 105. India Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 106. China Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 107. China Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 108. China Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 109. China Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 110. China Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 111. Japan Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 112. Japan Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 113. Japan Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 114. Japan Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 115. Japan Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 116. Australia Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 117. Australia Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 118. Australia Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 119. Australia Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 120. Australia Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 121. Vietnam Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 122. Vietnam Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 123. Vietnam Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 124. Vietnam Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 125. Vietnam Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 126. South Korea Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 127. South Korea Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 128. South Korea Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 129. South Korea Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 130. South Korea Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 131. Indonesia Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 132. Indonesia Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 133. Indonesia Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 134. Indonesia Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 135. Indonesia Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 136. Philippines Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 137. Philippines Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 138. Philippines Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 139. Philippines Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 140. Philippines Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 141. Middle East & Africa Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 142. Middle East & Africa Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 143. Middle East & Africa Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 144. Middle East & Africa Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 145. Middle East & Africa Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 146. Middle East & Africa Oral Proteins and Peptides Market Share (%), By Country, 2018-2032F
• Figure 147. Saudi Arabia Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 148. Saudi Arabia Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 149. Saudi Arabia Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 150. Saudi Arabia Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 151. Saudi Arabia Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 152. UAE Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 153. UAE Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 154. UAE Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 155. UAE Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 156. UAE Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 157. South Africa Oral Proteins and Peptides Market, By Value, In USD Billion, 2018-2032F
• Figure 158. South Africa Oral Proteins and Peptides Market Share (%), By Active Ingredient, 2018-2032F
• Figure 159. South Africa Oral Proteins and Peptides Market Share (%), By Formulation Type, 2018-2032F
• Figure 160. South Africa Oral Proteins and Peptides Market Share (%), By Delivery Technology, 2018-2032F
• Figure 161. South Africa Oral Proteins and Peptides Market Share (%), By Therapeutic Indication, 2018-2032F
• Figure 162. By Active Ingredient Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 163. By Formulation Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 164. By Delivery Technology Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 165. By Therapeutic Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024